In this edition:
PEARLY: AC followed by taxane + carboplatin in early TNBC
A-BRAVE: avelumab for early, high-risk TNBC
NATALEE: ribociclib + NSAI in node-negative, HR+/HER- early breast cancer
RxPONDER: AMH levels & chemotherapy + endocrine therapy in premenopausal, HR+/HER-, node-positive breast cancer
monarchE: prognostic value of ctDNA detection for abemaciclib + endocrine therapy
DESTINY-Breast06: T-DXd in HR+/ HER2-low/-ultralow metastatic breast cancer
postMONARCH: second-line abemaciclib + fulvestrant for HR+, HER2- advanced breast cancer
PATRICIA cohort C: palbociclib + trastuzumab + endocrine therapy in pretreated, HER2+, PAM50 luminal advanced breast cancer
EMERALD: eribulin + HER2 blockade for recurrent/metastatic HER2+ breast cancer
Please login below to download this issue (PDF)